Finding 496791 (2023-001)

Material Weakness
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2024-09-13
Audit: 319539
Organization: Overdose Lifeline, Inc. (IN)
Auditor: Pile CPAS

AI Summary

  • Core Issue: There is a material weakness in internal controls over prepaid expenses, leading to an overstatement of expenses due to misalignment of invoice timing.
  • Impacted Requirements: This finding violates GAAP principles, risking inaccurate financial reporting and potential non-compliance with federal grant requirements.
  • Recommended Follow-Up: Implement a corrective action plan to improve internal controls, enhance staff training, and conduct regular reviews and audits of accounts payable and prepaid supplies.

Finding Text

Finding 2023-001 Accounting for Prepaid Expenses Type of Finding: Material Weakness in Internal Control over Financial Reporting Criteria: According to accounting principles generally accepted in the United States of America ("GAAP"), an organization must have effective internal controls over accounting for prepaid expenses to ensure that transactions are recorded in the correct accounting period. This includes properly accounting for the timing of the receipt of prepaid supplies. Condition: Invoices for prepaid supplies were included in accounts payable for supplies that were not received in the same period. This resulted in an overstatement of expenses related to the prepaid supplies, as the expenses were not properly matched with the periods in which the supplies were actually received and used. Cause: The underlying cause of the condition was a failure to account for the timing of receipt for the supplies. This indicates a deficiency in the internal controls and procedures related to the recording of prepaid expenses. Possible or Known Effect: The effect of this condition was an overstatement of expenses, which could potentially mislead financial statement users and impact decision-making. This could also lead to inaccurate financial reporting and potential non-compliance with federal grant requirements. Questioned Costs: There are no specific questioned costs identified in this finding as the overstatement impacts the accuracy of financial reporting rather than a direct disallowed cost. However, the overstatement of expenses may affect the accuracy of financial statements and compliance with grant terms. Repeat Finding: This finding is not a repeat finding from the prior year. Recommendation: It is recommended that the organization implement a corrective action plan to address the internal control deficiencies identified. This plan should focus on revising procedures to ensure that prepaid supplies are accurately recorded in the period in which they are received. Additionally, enhancing training for staff involved in accounting for prepaid expenses will help ensure proper understanding and execution of these procedures. Regular reviews and reconciliations of accounts payable and prepaid supplies records should be conducted to prevent similar issues in the future. Finally, performing periodic audits of internal controls will help ensure ongoing compliance with accounting standards and grant requirements. Views of Responsible Officials: The Organizations’ Board and Executive Team consisting of the Chief Executive Officer (CEO) and the Chief Operating Officer (COO) and key Overdose Lifeline (ODL) Staff to include the independent bookkeeper and Grant and Finance Manager recognize the internal control deficiencies identified during the year 2023. As noted by the Independent Public Accounting Firm (Pile CPAs) significant improvements have occurred and in the first half of 2024 ODL implemented a new inventory accounting process through QuickBooks. This finding is addressed through this new accounting process. Overdose Lifeline moved from tracking inventory manually in excel spreadsheets to utilizing inventory management in Quickbooks Online (QBO). The process is: - Receipts: Once inventory is physically received, a QBO bill is entered identifying the quantity and cost of the items. - Shipments: Shipments are reflected on a weekly basis identifying the items and quantity shipped per item on a zero-dollar invoice. QBO utilizes FIFO (First In/First Out) methodology for inventory valuation. The physical inventory is reconciled to the QBO inventory counts monthly. Additionally the Grants and Finance Manager, Executive Team and other key personnel will conduct periodic audits of internal controls.

Categories

Equipment & Real Property Management

Other Findings in this Audit

  • 496767 2023-001
    Material Weakness
  • 496768 2023-002
    Significant Deficiency Repeat
  • 496769 2023-004
    Significant Deficiency
  • 496770 2023-003
    Significant Deficiency Repeat
  • 496771 2023-005
    Material Weakness
  • 496772 2023-001
    Material Weakness
  • 496773 2023-002
    Significant Deficiency Repeat
  • 496774 2023-004
    Significant Deficiency
  • 496775 2023-003
    Significant Deficiency Repeat
  • 496776 2023-001
    Material Weakness
  • 496777 2023-002
    Significant Deficiency Repeat
  • 496778 2023-004
    Significant Deficiency
  • 496779 2023-001
    Material Weakness
  • 496780 2023-002
    Significant Deficiency Repeat
  • 496781 2023-004
    Significant Deficiency
  • 496782 2023-001
    Material Weakness
  • 496783 2023-002
    Significant Deficiency Repeat
  • 496784 2023-004
    Significant Deficiency
  • 496785 2023-001
    Material Weakness
  • 496786 2023-002
    Significant Deficiency Repeat
  • 496787 2023-004
    Significant Deficiency
  • 496788 2023-001
    Material Weakness
  • 496789 2023-002
    Significant Deficiency Repeat
  • 496790 2023-004
    Significant Deficiency
  • 496792 2023-002
    Significant Deficiency Repeat
  • 496793 2023-004
    Significant Deficiency
  • 496794 2023-001
    Material Weakness
  • 496795 2023-002
    Significant Deficiency Repeat
  • 496796 2023-004
    Significant Deficiency
  • 1073209 2023-001
    Material Weakness
  • 1073210 2023-002
    Significant Deficiency Repeat
  • 1073211 2023-004
    Significant Deficiency
  • 1073212 2023-003
    Significant Deficiency Repeat
  • 1073213 2023-005
    Material Weakness
  • 1073214 2023-001
    Material Weakness
  • 1073215 2023-002
    Significant Deficiency Repeat
  • 1073216 2023-004
    Significant Deficiency
  • 1073217 2023-003
    Significant Deficiency Repeat
  • 1073218 2023-001
    Material Weakness
  • 1073219 2023-002
    Significant Deficiency Repeat
  • 1073220 2023-004
    Significant Deficiency
  • 1073221 2023-001
    Material Weakness
  • 1073222 2023-002
    Significant Deficiency Repeat
  • 1073223 2023-004
    Significant Deficiency
  • 1073224 2023-001
    Material Weakness
  • 1073225 2023-002
    Significant Deficiency Repeat
  • 1073226 2023-004
    Significant Deficiency
  • 1073227 2023-001
    Material Weakness
  • 1073228 2023-002
    Significant Deficiency Repeat
  • 1073229 2023-004
    Significant Deficiency
  • 1073230 2023-001
    Material Weakness
  • 1073231 2023-002
    Significant Deficiency Repeat
  • 1073232 2023-004
    Significant Deficiency
  • 1073233 2023-001
    Material Weakness
  • 1073234 2023-002
    Significant Deficiency Repeat
  • 1073235 2023-004
    Significant Deficiency
  • 1073236 2023-001
    Material Weakness
  • 1073237 2023-002
    Significant Deficiency Repeat
  • 1073238 2023-004
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.137 Community Programs to Improve Minority Health Grant Program $56,493
93.788 Opioid Str $19,750
21.027 Coronavirus State and Local Fiscal Recovery Funds $18,541